tetano
Editor, Senior Moderator
Clin Immunol. 2016 Mar 14. pii: S1521-6616(16)30035-3. doi: 10.1016/j.clim.2016.03.008. [Epub ahead of print]
[h=1]A Plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T Cell response in healthy adults.[/h] Pillet S[SUP]1[/SUP], Aubin ?[SUP]2[/SUP], Tr?panier S[SUP]2[/SUP], Bussi?re D[SUP]2[/SUP], Dargis M[SUP]2[/SUP], Poulin JF[SUP]3[/SUP], Yassine-Diab B[SUP]3[/SUP], Ward BJ[SUP]2[/SUP], Landry N[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Recent issues regarding efficacy of influenza vaccines have re-emphasized the need of new approaches to face this major public health issue. In a phase 1-2 clinical trial, healthy adults received one intramuscular dose of a seasonal influenza plant-based quadrivalent virus-like particle (QVLP) vaccine or placebo. The hemagglutination inhibition (HI) titers met all the European licensure criteria for the type A influenza strains at the 3μg/strain dose and for all four strains at the higher dosages 21days after immunization. High HI titers were maintained for most of the strains 6months after vaccination. QVLP vaccine induced a substantial and sustained increase of hemagglutinin-specific polyfunctional CD4 T cells, mainly transitional memory and TEMRA effector IFN-γ+ CD4 T cells. A T cells cross-reactive response was also observed against A/Hong-Kong/1/1968 H3N2 and B/Massachusetts/2/2012. Plant-based QVLP offers an attractive alternative manufacturing method for producing effective and HA-strain matching seasonal influenza vaccines. NCT01991587.
Copyright ? 2015. Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Nicotiana benthamiana; Plant-derived quadrivalent influenza vaccine; cell-mediated immunity; cross-reactive response; safety and immunogenicity; virus-like particles
PMID: 26987887 [PubMed - as supplied by publisher]
[h=1]A Plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T Cell response in healthy adults.[/h] Pillet S[SUP]1[/SUP], Aubin ?[SUP]2[/SUP], Tr?panier S[SUP]2[/SUP], Bussi?re D[SUP]2[/SUP], Dargis M[SUP]2[/SUP], Poulin JF[SUP]3[/SUP], Yassine-Diab B[SUP]3[/SUP], Ward BJ[SUP]2[/SUP], Landry N[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Recent issues regarding efficacy of influenza vaccines have re-emphasized the need of new approaches to face this major public health issue. In a phase 1-2 clinical trial, healthy adults received one intramuscular dose of a seasonal influenza plant-based quadrivalent virus-like particle (QVLP) vaccine or placebo. The hemagglutination inhibition (HI) titers met all the European licensure criteria for the type A influenza strains at the 3μg/strain dose and for all four strains at the higher dosages 21days after immunization. High HI titers were maintained for most of the strains 6months after vaccination. QVLP vaccine induced a substantial and sustained increase of hemagglutinin-specific polyfunctional CD4 T cells, mainly transitional memory and TEMRA effector IFN-γ+ CD4 T cells. A T cells cross-reactive response was also observed against A/Hong-Kong/1/1968 H3N2 and B/Massachusetts/2/2012. Plant-based QVLP offers an attractive alternative manufacturing method for producing effective and HA-strain matching seasonal influenza vaccines. NCT01991587.
Copyright ? 2015. Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Nicotiana benthamiana; Plant-derived quadrivalent influenza vaccine; cell-mediated immunity; cross-reactive response; safety and immunogenicity; virus-like particles
PMID: 26987887 [PubMed - as supplied by publisher]